Updated:
The US vaccine manufacturer Moderna has presented positive interim results of a clinical study with its corona vaccine in children.
Massachusetts – In six to eleven year olds, the vaccine produced a “strong” immune response, Moderna said on Monday. The children had a “robust neutralizing antibody response” one month after the second vaccination dose.
The biotechnology company also spoke of an “advantageous safety profile”. The children would have tolerated the vaccine well. Moderna boss Stéphane Bancel was “encouraged” by the study results. The company plans to have data on the clinical trial with more than 4,750 participants “soon” with the US Food and Drug Administration, the European Medicines Agency (EMA) and other regulatory agencies.
The Corona vaccine from Moderna, like the vaccine from Biontech and Pfizer, is based on so-called mRNA technology. The FDA’s independent vaccines committee will look into a possible approval of the vaccine from Biontech and Pfizer for five- to eleven-year-olds on Tuesday.
The US government hopes to start a large-scale vaccination campaign for this age group in early November. Biontech and Pfizer have also applied for approval of their corona vaccine for this age group in the EU.
fs / mid
#Study #Moderna #vaccine #children #Strong #immune #response #coronavirus